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Atrial fibrillation (AF) is associated with a substantial
morbidity that is primarily related to troublesome symp-
toms, heart failure, and thromboembolic events. Drug and
nonpharmacologic therapies that control rhythm or rate
usually ameliorate the troublesome symptoms and heart
failure, and randomized clinical trials have shown that oral
anticoagulation with warfarin reduces the risk of thrombo-
embolic events (1–5). However, when AF is thought to be
completely suppressed or cured, usually equated with both
the absence of clinical symptoms and the presence of only
sinus rhythm documented with routine office electrocardio-
grams (ECGs) and an occasional 24-h ambulatory ECG or
even an ECG event monitor for one month, physicians
often stop anticoagulation in an effort to avoid the perceived
unnecessary exposure of patients to the risks, burdens, and
inconveniences of warfarin therapy. The question is whether
such surveillance is sufficient to permit reliable conclusions
about the suppression or cure of AF. The concern, of course,
is that patients may have asymptomatic recurrences of AF,
thereby exposing them to risk of ischemic stroke and other
thromboembolic events.
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Although it has long been known that asymptomatic AF
occurs (6), the magnitude of this problem is only beginning
to be appreciated. Surveillance ECGs obtained at office
visits are an insensitive method of detecting asymptomatic
AF. Furthermore, a history of symptomatic AF in the past
in no way guarantees that recurrences will be symptomatic
(7,8). When routine transtelephonic recordings are per-
formed, the incidence of asymptomatic AF recurrence may
be as high as 50% (6,7). Recent studies have reported an
even higher incidence of asymptomatic AF when pacemaker
memory data are used for detection (9,10), and treatment of
AF with drug therapy may contribute to this incidence by
providing rate control during recurrence or by shortening
the duration of the recurrence (11).
In this issue of the Journal, Israel et al. (12), using a
sophisticated pacemaker to detect recurrent AF, confirmed
a very high incidence of asymptomatic AF. Of particular
note, this included episodes lasting more than 48 h in 17%
of the patients studied. Additionally, even among those
patients free of AF for more than three months, 16%
subsequently had asymptomatic AF lasting more than 48 h.
It may be argued that AF is more likely to be asymptomatic
in pacemaker patients. Patients with complete atrioventric-
ular block, for example, will not develop a rapid or irregular
ventricular response rate. However, the message of Israel’s
study is that the overall recurrence rate of AF (symptomatic
and asymptomatic) is remarkably high, often for relative
long periods (48 h), and occurs even after relatively long
quiescent periods (3 months).
These findings, together with those of previous studies,
have important implications. Clearly, great caution must be
exercised when AF is judged “suppressed” or “cured.”
Certainly, as demonstrated by the Atrial Fibrillation
Follow-up Investigation of Rhythm Management (AF-
FIRM) study, in which 57% of the strokes in the rhythm
control arm occurred in patients who had stopped taking
warfarin, patients with risk factors for stroke whose AF is
thought to be suppressed remain at considerable risk if
warfarin is stopped (13). Presumably, this is largely ex-
plained by the occurrence of asymptomatic AF.
In light of this perspective, there are really two principal
issues, the first of which is: Once there is an indication for
warfarin in patients with a history of AF, should it ever be
permanently stopped? The answer seems to be no. But how
does this apply to patients after “successful” surgical Maze or
catheter ablation procedures to cure AF? One would like to
think that “cure” means never having to take warfarin again.
However, with a dearth of data on the occurrence of
asymptomatic AF in those patients, the admonition “once
on warfarin, always on warfarin” may apply to virtually all
patients with a history of AF and risk factors for stroke.
Perhaps the only patients who do not need lifelong oral
anticoagulation are those without associated risk factors for
stroke and those whose AF occurred only in the context of
a discrete and transient precipitating event (for example,
after open heart surgery or thyrotoxicosis).
The considerable difficulties (prolonged dose titration,
interaction with numerous drugs and foods, the need for
anticoagulation monitoring, among others) in administering
warfarin and maintaining an international normalized ratio
in the therapeutic range lead to the second principal issue:
Are there acceptable alternative therapies to warfarin to
prevent thromboembolism? Potential alternatives are cur-
rently under investigation. During AF, most clots are
thought to form in the left atrial appendage (14). Therefore,
one approach is to occlude the left atrial appendage using
endocardial catheter techniques (15). Another even more
aggressive approach is to excise the left atrial appendage
surgically (16,17). At present, these two approaches seem
most applicable to patients at high risk for ischemic stroke
who either cannot take warfarin or in whom warfarin has
proven ineffective, and for whom cure of the atrial fibrilla-
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tion is not feasible. Perhaps the most important and
practical alternative to warfarin therapy involves the new
oral direct thrombin-inhibiting anticoagulants. Recently
presented data from the Stroke Prevention Oral Thrombin
Inhibitor in Atrial Fibrillation III (SPORTIF III) trial (18),
a very large clinical trial of patients with AF at risk for
ischemic stroke, demonstrated that compared with warfarin,
the direct thrombin inhibitor ximelagatran was at least as
effective in preventing stroke, had less bleeding, and had a
favorable rate of major and minor bleeding. Moreover,
compared with warfarin, ximelagatran does not require dose
titration or adjustment, has rapid onset and offset of action,
does not require monitoring for anticoagulation efficacy, and
to date, has almost no documented interactions with foods
or drugs. If the safety and efficacy of the oral direct
thrombin inhibitors continue to be supported by subsequent
studies, they should make it far easier for physicians to
provide safe and effective oral anticoagulant therapy to
patients with fibrillation who need it.
In summary, Israel et al. (12) have provided yet more
authoritative data on the enormity of the problem of
asymptomatic AF. The implications for treatment are clear,
namely that apparent freedom from AF does not, per se,
obviate the need for oral anticoagulation. The need to
provide safe and effective oral anticoagulant therapy is
crucially important, especially with the increasing numbers
of patients with AF, most of whom are elderly and at risk
for ischemic stroke (19).
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